ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction ...

Decades after early trials seemed to close the book on vitamin C as a cancer treatment, a member of a group of determined researchers is receiving the therapy himself.

(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with ...

Intensive chemotherapy provided the longest overall and progression-free survival, especially in blast phase MPN patients. Venclexta-based treatments did not significantly improve progression-free ...

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...

Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...

The phase 3 VERONA trial did not meet the primary endpoint of overall survival. Topline data were announced from a phase 3 trial evaluating venetoclax (Venclexta ®) plus azacitidine for patients with ...

Azacitidine is incorporated predominantly—around 80% to 90%—not into DNA, but into RNA, which causes damage. The researchers have now demonstrated that damage in messenger RNA (mRNA), which transports ...

Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. An all-oral regimen of decitabine-cedazuridine (DEC-C ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...